195 related articles for article (PubMed ID: 30727921)
1. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
[TBL] [Abstract][Full Text] [Related]
2. Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment.
Ahorlu CSK; Koka E; Adu-Amankwah S; Otchere J; de Souza DK
BMC Public Health; 2018 Feb; 18(1):238. PubMed ID: 29433461
[TBL] [Abstract][Full Text] [Related]
3. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
[TBL] [Abstract][Full Text] [Related]
4. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
Biritwum NK; Frempong KK; Verver S; Odoom S; Alomatu B; Asiedu O; Kontoroupis P; Yeboah A; Hervie ET; Marfo B; Boakye DA; de Vlas SJ; Gyapong JO; Stolk WA
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007115. PubMed ID: 31398203
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
[TBL] [Abstract][Full Text] [Related]
6. Factors determining non-compliance to mass drug administration for lymphatic filariasis elimination in endemic districts of Nepal.
Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Devkota P; Mishra D; Ghimire YC; Gelal K; Mishra R; Paudel R; Wagle RR
J Nepal Health Res Counc; 2014; 12(27):124-9. PubMed ID: 25726571
[TBL] [Abstract][Full Text] [Related]
7. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
Lupenza ET; Gasarasi DB; Minzi OM
PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
[TBL] [Abstract][Full Text] [Related]
9. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.
Njomo DW; Kimani BW; Kibe LW; Okoyo C; Omondi WP; Sultani HM
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300
[TBL] [Abstract][Full Text] [Related]
10. Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India.
Bashar A; Nandekar SV; Shrivastava P; Singh RN; Srikrishnan P
J Vector Borne Dis; 2023; 60(3):307-316. PubMed ID: 37843242
[TBL] [Abstract][Full Text] [Related]
11. Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.
Manyeh AK; Ibisomi L; Ramaswamy R; Baiden F; Chirwa T
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007009. PubMed ID: 32804967
[TBL] [Abstract][Full Text] [Related]
12. Assessing factors influencing communities' acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana.
Niles RA; Thickstun CR; Cox H; Dilliott D; Burgert-Brucker CR; Harding-Esch EM; Clementson N; Sampson A; Alexandre JS; Morice Trejos AC; Scholte RGC; Krentel A
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009596. PubMed ID: 34543269
[TBL] [Abstract][Full Text] [Related]
13. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
Minetti C; Tettevi EJ; Mechan F; Prada JM; Idun B; Biritwum NK; Osei-Atweneboana MY; Reimer LJ
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006994. PubMed ID: 30608931
[TBL] [Abstract][Full Text] [Related]
14. Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia.
Titaley CR; Damayanti R; Soeharno N; Mu'asyaroh A; Bradley M; Lynam T; Krentel A
Parasit Vectors; 2018 May; 11(1):315. PubMed ID: 29801511
[TBL] [Abstract][Full Text] [Related]
15. Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d'Ivoire.
Loukouri A; Méité A; Koudou BG; Goss CW; Lew D; Weil GJ; N'Goran EK; Fischer PU
PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008642. PubMed ID: 32976514
[TBL] [Abstract][Full Text] [Related]
16. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
[TBL] [Abstract][Full Text] [Related]
17. Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007365. PubMed ID: 31009482
[TBL] [Abstract][Full Text] [Related]
18. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
[TBL] [Abstract][Full Text] [Related]
19. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
Biritwum NK; de Souza DK; Marfo B; Odoom S; Alomatu B; Asiedu O; Yeboah A; Hervie TE; Mensah EO; Yikpotey P; Koroma JB; Molyneux D; Bockarie MJ; Gyapong JO
PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005280. PubMed ID: 28333930
[No Abstract] [Full Text] [Related]
20. Knowledge and practice related to compliance with mass drug administration during the Egyptian national filariasis elimination program.
Abd Elaziz KM; El-Setouhy M; Bradley MH; Ramzy RM; Weil GJ
Am J Trop Med Hyg; 2013 Aug; 89(2):260-4. PubMed ID: 23751402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
